Results 151 to 160 of about 242,665 (269)

Toward Nano‐Nutritional Medicine: A Remotely Activated Trans‐Vaccenic Acid‐Based Lipid Nanoparticles for Enhancing Immune Checkpoint Blockade Therapy

Advanced Science, EarlyView.
Eutectic mixtures from trans‐vaccenic acid (TVA) and stearic acid, which served as phase‐change material to encapsulate IR780, forming NIR‐responsive nanoparticles. IR780@TVA LNPs induce photothermal therapy and initiate adaptive anti‐tumor immunity.
Kang Liu, Yunlong Li, Hanmeng Liu, Peng Zhang, Mingjing Wang, Quanwei Sun, Wenshuo Yang, Zhengwei Song, Song Tan, Ye Yang, Peng She, Dengke Yin, Wei Shen   +12 more
wiley   +1 more source

Pregnancy Outcomes After in Utero Exposure to Immune Checkpoint Inhibitors. [PDF]

Curr Oncol
Bou Zerdan M, Kfoury B, Aoun E, Hmaidan SD, Wilke RN, How JA, Woodard TL, Soliman PT, McKenzie LJ.   +8 more
europepmc   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source

Immune Profiling Identifies Inflammatory Signatures in Immune Checkpoint Inhibitor-Related Myocarditis. [PDF]

JACC CardioOncol
Daoudlarian D, Boughdad S, Bartolini R, Latifyan S, Doms J, Bouchaab H, Abdelhamid K, Ferahta N, Mederos Alfonso NN, Joo V, Stamatiou A, Mencarelli L, Etienne N, Stravodimou A, Zaman K, Perreau M, Fenwick C, Shabafrouz K, Pantaleo G, Peters S, Obeid M.   +20 more
europepmc   +1 more source

Targeting Lactate‐Driven Stromal Autophagy via MCT1 Disrupts the Immunosuppressive Niche and Sensitizes Pancreatic Cancer to PD‐1 Blockade

Advanced Science, EarlyView.
Tumor‐derived lactate activates PSCs through MCT1‐mediated Vps34 lactylation and autophagy. These activated PSCs secrete CXCL9/10, upregulating PD‐1 on CD8+ T cells via the CXCR3/STAT3 axis to foster immunosuppression. Disrupting this metabolic crosstalk by targeting MCT1 effectively sensitizes pancreatic cancer to PD‐1 blockade, presenting a promising
Wenfeng Zhuo, Rong Hu, Yuhang Hu, Ping Hu, Shengbo Han, Guozheng Lv, Zhu Zeng, Yong Zhao, Yang Li, Yan Huang, Yingsong Zhao, Hongda Wang, Guangyu Zhao, Eryang Zhao, Gang Zhao   +14 more
wiley   +1 more source

Immune Checkpoint-Based Therapies in Colorectal Cancer-Current Approaches and Future Perspectives. [PDF]

Int J Mol Sci
Nakielska K, Plewka J, Lenart M.
europepmc   +1 more source

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

Advanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao, Dongdong Liu, Haishan Gao, Chenyang Qin, Wen Zhang, Ziyun Lu, Dongxia Tan, Yuxiu Qu, Yusong Liu, Zhiran Zou, Hongtao Yu, Wei Qi   +11 more
wiley   +1 more source

Pharmacological Inhibition of FKBP51 Mitigates Early Life Adversity‐Induced Social Deficits in Male Mice

Advanced Science, EarlyView.
Early life adversity triggers persistent social subordination and brain‐wide molecular dysregulation. Pharmacological inhibition of the stress‐mediator FKBP51 during the adversity period prevents these long‐term deficits and restores normative social hierarchy.
Joeri Bordes, Xiuqi Ji, Serena Gasperoni, Choham Sudre‐Chinsky, Amirali Kalbasi, Daniela Harbich, Cornelia Flachskamm, Paula Fontanet, Sowmya Narayan, Manfred Uhr, Christian Namendorf, Camilla Bellone, Alon Chen, Felix Hausch, Juan Pablo Lopez, Mathias V. Schmidt   +15 more
wiley   +1 more source

Immune checkpoint TIM-3 in tumor immunotherapy. [PDF]

Acta Biochim Biophys Sin (Shanghai)
Ma S, Zhu M, Ma C, Li C.
europepmc   +1 more source

Targeting DNGR‐1 with Fangchinoline Elevates Dendritic Cell Antigen Cross‐Presentation‐Mediated Antitumor Immunity in Melanoma

Advanced Science, EarlyView.
Fangchinoline is identified as a small‐molecule DNGR‐1 modulator that enhances dendritic‐cell cross‐presentation of tumor antigens. By engaging DNGR‐1 and activating Syk–Nox2 signaling, it promotes phagosomal ROS, antigen escape, MHC‐I presentation, and CD8+ T‐cell priming, thereby strengthening antitumor immunity and sensitizing tumors to PD‐1 ...
Yuan Liao, Zhenyang Ren, Jing Zhou, He Luo, Yuling Li, Dan Chen, Yuxiao Jiang, Canzhe Li, Mengyi Zheng, Anqi Li, Yao Wang, Yang Zhang, Dingye Wang, Yanjun Jiang, Jiangyong Gu, Biaoyan Du, Yafei Shi, Fang Liu, Jianyong Xiao, Kun Wang   +19 more
wiley   +1 more source